Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 8, 2008, Pages 760-768

  Walker, Alexander M ^a,b   Koro, Carol E ^c   Landon, Joan ^d  

^a World Health Information Science Consultants LLC   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d i3 Drug Safety   (United States)

Author keywords

Coronary revascularization; Insulin; Metformin; Myocardial infarction; Pioglitazone; Retrospective cohort study; Rosiglitazone; Sulfonylurea; Type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT;

COHORT STUDIES; CORONARY DISEASE; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 50249169522     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1598     Document Type: Article

References (8)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352(9131): 837-853.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352(9131): 854-865.
3. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; (Epub ahead of print), DOI: 10.1002/pds.1443
4. Johannes CB, Koro, CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmcoepidemiol Drug Saf 2007; 16(5): 504-512.
5. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; DOI:10.1002/pds 1470
6. Xu Y, Vallarino, C, Baran RW, Spanheimer R. Risk of stroke and myocardial infarction is reduced in patients with type 2 diabetes treated with pioglitazone: results of a retrospective claims-based study. Online abstract for the 43rd EASD Annual Meeting, Amsterdam 17-21 September 2007. http://www.easd.org/customfiles/43rd/abstracts/documents/ 1257.doc [accessed 30 August 2007).
7. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 2007; 357: 844-846.
8. Walker AM, Koro CE, McAfee A. Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiol Drug Saf 2007; 16: 1313-1314.